Therefore, despite the recent updates in guidelines indicating that the addition of immunotherapy has improved the prognosis for patients with advanced NSCLC, those with negative PD-L1 expression continue to face limited OS, significant toxic side effects, and challenges related to immune resistance. This evidence concerns the gene CD274 and non-small cell lung carcinoma.